Consumer Perspectives on the Informed Consent of Off-label Drug Use in South Korea |
Lee, Iyn-Hyang
(College of Pharmacy, Yeungnam University)
Kye, Seunghee (Department of Preventive Medicine & Public Health, School of Medicine, Ajou University) Je, Nam Kyung (College of Pharmacy, Pusan National University) Lee, Sukhyang (College of Pharmacy, Ajou University) |
1 | Brosgart CL, Mitchell T, Charlebois E, et al. Off-label drug use in human immunodeficiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(1):56-62. DOI |
2 | Haw C, Stubbs J. A survey of the off-label use of mood stabilizers in a large psychiatric hospital. J Psychopharmacol 2005;19(4):402-7. DOI |
3 | Leslie DL, Rosenheck R. Off-label use of antipsychotic medications in medicaid. Am J Manag Care 2012;18(3): e109-17. |
4 | Lindell-Osuagwu L, Korhonen MJ, Saano S, et al. Offlabel and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 2009;34(3):277-87. DOI ScienceOn |
5 | Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166(9): 1021-26. DOI |
6 | Stafford RS. Regulating Off-Label Drug Use--Rethinking the Role of the FDA. New Engl J Med 2008;358(14):1427-29. DOI |
7 | Turner S. Unregistered and off-label drug use in paediatric inpatients Aust J Hosp Pharm 1999;29(5):265-68. DOI |
8 | Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. New Engl J Med 2001;344(1):38-47. DOI |
9 | Liang BA, Mackey T. Health care policy. Reforming offlabel promotion to enhance orphan disease treatment. Science 2010;327(5963):273-4. DOI |
10 | Stone KJ, Viera AJ, Parman CL. Off-label applications for SSRIs. Am Fam Physician 2003;68(3):498-504. |
11 | Weeks AD, Fiala C, Safar P. Misoprostol and the debate over off-label drug use. Int J Obstet Gynaecol 2005;112(3): 269-72. DOI |
12 | Shin JY, Jung SY, Park BJ. Off-label drug use and its implications for evidence-based decising making. J Pharmacoepidem Risk Manage 2010;3:1-6. |
13 | Novak E, Allen PJ. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics. Pediatr Nurs 2007;33(1):64-70. |
14 | Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 2006;5(5):703-18. DOI |
15 | Maglione M, Maher AR, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Rockville (MD): Agency for Healthcare Research and Quality (US), 2011. |
16 | Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 2012;68(1):21-8. DOI |
17 | Ufer M, Kimland E, Bergman U. Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf 2004;13(3):147-52. DOI |
18 | Steinman MA, Bero LA, Chren MM, et al. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 2006;145(4):284-93. DOI |
19 | Ventola CL. Off-label drug information: regulation, distribution, evaluation, and related controversies. P T 2009; 34(8):428-40. |
20 | Wilkes M, Johns M. Informed consent and shared decision-making: A requirement to disclose to patients offlabel prescriptions. PLoS Medicine 2008;5(11):1553-56. |
21 | Lee IH, Seo M, Lee YS, et al. Development of regulation system for off-label drug use. Yakhak Hoeji 2014;58(2):112-24. |
22 | Dresser R, Frader J. Off-label prescribing: A call for heightened professional and government oversight. J Law Med Ethics 2009;37(3):476-96. DOI |
23 | EURORDIS. EURORDIS response to the European Commission Public Consultation "Legal proposal on information to patients". 2008. |
24 | Mithani Z. Informed consent for off-label use of presciption medications. Am Med Assoc J Ethics 2012;14(7):576-81. |
25 | Meadows WA, Hollowell BD. 'Off-label' drug use: an FDA regulatory term, not a negative implication of its medical use. Int J Impot Res 2008;20(2):135-44. DOI |
26 | Mukattash TL, Millership JS, Collier PS, et al. Public awareness and views on unlicensed use of medicines in children. Br J Clin Pharmacol 2008;66(6):838-45. DOI |
27 | Bang V, Mallad A, Kannan S, et al. Awareness about and views of parents on the off-label drug use in children. Int J Risk Saf Med 2014;26(2):61-70. |
28 | Lenk C, Koch P, Zappel H, et al. Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics. Eur J Pediatr 2009;168(12):1473-8. DOI |